Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study

In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.